RE: Q3 2024 Earnings Call Transcript
Reading the transcript it was interesting to read about the preparation for GBM and NSCLC studies.
They specifically say the the prep has been done for GBM and they are working on it for NSCLC.
That is interesting as that means they are further head with GBM. Plus GBM is ugly. 15 m average life expectancy from time of diagnosis.
It would be considered a priority kind of condition to get new protocols approved and running for a phase 1a.
I hope that is a good sign. That they can get cash and run with GBM promptly. The GBM mice data that they published years ago was really good. Not just a small mice trial but a very large writeup on treating GBM with TLD-1433.
If only they could connect with some wealthy people whose families have been impacted by GBM. Those would by motivated investors.